TOLEDO, Ohio, Aug. 15, 2017 /PRNewswire/ — VentureMed Group®, Inc., (“VMG” or the “Company”) a medical device company developing and commercializing next-generation endovascular products to treat patients suffering from peripheral artery disease (PAD), today announced it had raised $15 million in new equity financing. […]
Tag: PAD
QT Vascular begins enrollment in US pivotal study of its drug-coated peripheral balloon
SINGAPORE, July 31, 2017 /PRNewswire/ — QT Vascular Ltd., together with its subsidiaries (the “Company”), announced it has started enrollment in its United States (“US“) pivotal clinical study. The study will evaluate the Company’s drug coated balloon (“DCB“), the Chocolate Touch®, for use in […]
Spectranetics (SPNC) Secures FDA Approval of Stellarex Drug-Coated Balloon
COLORADO SPRINGS, Colo., July 26, 2017 (GLOBE NEWSWIRE) — The Spectranetics Corporation (NASDAQ:SPNC) today announced receipt of U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) of the Stellarex™ drug-coated balloon (DCB), designed to restore and maintain blood flow to the superficial […]
SurModics (SRDX) Receives IDE Approval To Initiate Pivotal Trial Of The Surveil Drug-Coated Balloon
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has received an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to initiate a pivotal […]
BIOTRONIK US Announces Pivotal Trial Results of the Pulsar-18 Stent with 4-French Delivery System
NEWS PROVIDED BY BIOTRONIK Jul 03, 2017, 10:00 ET LAKE OSWEGO, Ore., July 3, 2017 /PRNewswire/ — BIOTRONIK today announced the results of the BIOFLEX-I clinical study and availability of Pulsar®-18 for the treatment of patients with peripheral artery disease (PAD). Pulsar-18 is the only superficial […]
Heart Endovascular & Rhythm of Texas Begins First Commercial, FDA-Cleared, In-Patient Use of DABRA™ to Treat Peripheral Artery Disease
SAN ANTONIO–(BUSINESS WIRE)–Today, the Heart Endovascular & Rhythm of Texas announced its latest collaboration with Ra Medical Systems, makers of cardiovascular and dermatology catheters and excimer lasers, to use its groundbreaking DABRA™ System for the treatment of Peripheral Artery Disease […]
Shockwave Medical Announces U.S. Commercial Availability Of Lithoplasty System And Enrollment Of First Patient In DISRUPT PAD III Global Clinical T
FREMONT, Calif.–(BUSINESS WIRE)–Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today announced two milestones for its Lithoplasty® System for the treatment of calcified plaque in patients with peripheral artery disease (PAD): enrollment of the first patient in […]
Avera Names Myles Greenberg, MD, as CEO of Alucent Medical
SIOUX FALLS, S.D.–(BUSINESS WIRE)–Myles D. Greenberg, MD, was named President and CEO of Alucent Medical, Inc., a new company licensed to develop a novel drug/device combination therapy for the treatment of peripheral vascular disease (PVD). The treatment, Natural Vascular Scaffolding […]
RA Medical’ DABRA Begins First Commercial, FDA-Cleared, In-Patient Use
NEW ORLEANS, La.–(BUSINESS WIRE)–Ra Medical Systems, makers of cardiovascular and dermatology catheters and excimer lasers, today announced the commercial launch in the United States of the Company’s groundbreaking DABRA™ System for the treatment of Peripheral Artery Disease. This follows FDA […]
FDA Grants Market Clearance to RA Medical’s New PAD System
CARLSBAD, Calif.–(BUSINESS WIRE)–In an effort to battle Peripheral Artery Disease (PAD), the leading cause of limb amputations, the Food and Drug Administration (FDA) announced today that it has granted market clearance to Ra Medical Systems, makers of excimer lasers and […]